title: [Cell proliferation and glial fibrillary acidic protein in brain tumors].
abstract: The results of histoautoradiographic and immunohistochemical studies of biopsy specimens of 15 brain tumours are reported. The specimens were labeled with 3H-thymidine using an in vitro technique. Meningiomas, oligodendrogliomas and well differentiated astrocytomas showed a median S-phase fraction of about 1%. In contrast, the labeling indices of 4 from 7 anaplastic astrocytomas were higher (2.1, 3.0, 3.5, 11.4). With increasing degree of malignancy the proliferative heterogeneity of the tumours increases. In every glioma varying amounts of glial fibrillary acidic protein (GFAP) were detected immunohistochemically (PAP technique). In 3 high-grade gliomas (2 glioblastomas, 1 anaplastic astrocytoma) an inverse relation of the investigated parameters (high S-phase fraction, low GFAP expression) was found. An exact prediction on biological behaviour of an individual tumour by GFAP detection immunohistochemically is not possible, because a high GFAP content can be detected also in some malignant tumours. However, the 3H-thymidine labeling indices of viable parts of the tumours, probably reflecting the growth fraction seem to be clinically important parameters, especially in respect to the prognosis.
mesh_terms: D000293:Adolescent; D000328:Adult; D001254:Astrocytoma / Q000032:analysis; D001345:Autoradiography; D001932:Brain Neoplasms / Q000032:analysis* / Q000473:pathology; D002455:Cell Division; D002471:Cell Transformation, Neoplastic / Q000175:diagnosis; D002675:Child, Preschool; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis*; D006651:Histocytochemistry; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008579:Meningioma / Q000032:analysis; D008875:Middle Aged; D009837:Oligodendroglioma / Q000032:analysis; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
chemical_list: D005904:Glial Fibrillary Acidic Protein; D014316:Tritium; D013936:Thymidine
vernacular_title: Zellproliferation und Expression des sauren Gliafaserproteins (GFAP) in Hirntumoren.